

University of Wisconsin-Madison Institutional Biosafety Committee

Minutes of Regular Meeting Open Session

Date: 8/6/2025

Present: Peter Halfmann, Matt Reynolds, Donna Neumann, Yevgenya Grinblat, Andrea Ladd, Warren Rose, Amita Kapoor, Gregory Gauthier, Ryan Stoffel, Garret Suen, Joel Malak, Clint Morgan, Barak Blum, Steve Garvis

Consultants: Tony Mcgrath, Lissa Koop, Darren Berger, Christina Pier, Carrie Ensrud, John Cejka, Quin Koehl

OBS: Tony Mcgrath, David Dyer, Karen Demick, Christina Pier, Andrea Ladd, Louise Meske, Stephanie Kutz, Tara Schnell, Megan Dixon, Erin Plisch, Donald Busalacchi, Carrie Ensrud, Kathy Krasny, Quin Koehl

Guests: Sarah Johnson-Schlueter, CALS

Call to order: The meeting was called to order by Garret Suen, at Zoom at 1:32 PM

Announcements: The IBC meeting is open to the public.

Review of Minutes: A motion to approve the open session minutes of the following IBC meetings was Unanimously adopted.

Institutional Biosafety Committee meeting on (7/23/2025)

Greg Gauthier, absent Steve Garvis, absent Yevgenya Grinblat, absent Joel Malak, absent

Approval of Registered Protocols: A motion to approve registered protocols was Unanimously adopted

Greg Gauthier, absent Steve Garvis, absent Yevgenya Grinblat, absent

Other business - open session

- **Agenda Items - Documents For Open Session:**
- **Executive Summary_proposed changes to reduce IBC workload_080425.docx**
- **List of Registered Protocols_060425-070925_AM.xlsx**
- **List of Registered Protocols_060425-070925_GP.xlsx**

Review of research protocols - open session

? B00001211

? B00001217

Review of research amendments - open session

? B00000019-AM021

? B00000044-AM016

? B00000124-AM009

? B00000173-AM017

? B00000205-AM018

? B00000424-AM008

? B00000475-AM019

? B00000492-AM028

? B00000514-AM008

? B00000537-AM004

? **B00000573-AM004**

? **B00000665-AM005**

? **B00000799-AM006**

? **B00001010-AM003**

? **B00001080-AM004**

? **B00001160-AM002**

Announcements

null

The meeting adjourned 2:39 PM

- **Bio Protocol Number: B00001211**

PI Name: [REDACTED]

Protocol Title: Molecular Pathogenesis of Emerging Infections for RG3 organisms.

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absent Peter Halfmann, abstain

Biosafety Level: BSL3; ABSL3; ABSL3; BSL3; BSL1;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-b); (III-D-1-a)(III-D-1-b);

Summary of IBC Review: The laboratory studies emerging pathogens of humans and animals for vaccine development. This new protocol specifically covers work with Mycobacteria at BSL3 that had previously been covered by biosafety protocol B00000492. No new research activities are proposed. Biosafety is adequately addressed. Minor clarifications are requested in the constructs table.

- **Bio Protocol Number: B00001217**

PI Name: Athena Nghiem

Protocol Title: Total coliform and Escherichia coli assay

Motion: IBC approved with contingencies

Motion Made By: Amita Kapoor

Motion Seconded By: Barak Blum

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absent

Biosafety Level: BSL1; BSL1;

Containment Equipment: Chemical fume hood; Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: null

NIH Guidelines:

Summary of IBC Review: This is a new protocol for a laboratory that studies coliform and E. coli in groundwater samples. No work with recombinant materials is proposed. The IBC considered source, containment, and inactivation of groundwater samples.

- **Bio Protocol Number: B00000019-AM021**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 021 for Immune response against mycobacterial infections and neuroimmunology of the Central Nervous System

Motion: IBC approved with contingencies

Motion Made By: Warren Rose

Motion Seconded By: Steve Garvis

Committee Action: Adopted by majority by voice vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absent

Biosafety Level: ABSL2; ABSL2; BSL2; BSL2; BSL2; BSL1; BSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; BSL1; ABSL1; BSL1; BSL2; ABSL2; ABSL2, BSL2; BSL2; ABSL2; BSL1; BSL2; BSL2; BSL1; BSL2; BSL2; BSL2; BSL2; ABSL2, BSL2; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC), Other - negative pressure BioBubble (both the BioBubble and the BSC containment equipments are certified annually); Chemical fume hood; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical

fume hood; Not applicable; Chemical fume hood; Not applicable; Not applicable;
Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work requires NIH approval under the NIH Guidelines. A Minor Action will be submitted. Final approval will be withheld until NIH approval is granted.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E-3); (III-E-3); (III-E-1); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1); (III-F-4) (III-F-5);

Summary of IBC Review: The laboratory studies the regulation of neuroinflammation in the nervous system and granuloma formation in immune diseases and infections. In this renewal, work with Mycobacteria at BSL3 is removed. The IBC supports work with highly attenuated strains of M. tuberculosis at BSL2; a Minor Action request will be submitted for NIH-OSP approval of the downgrade.

- **Bio Protocol Number: B00000044-AM016**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 016 for Pathogenesis of eye infections and antimicrobial, and gene therapy for ocular disease

Motion: IBC approved with contingencies

Motion Made By: Peter Halfmann

Motion Seconded By: Yevgenya Grinblat

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absent

Biosafety Level: BSL2; ABSL2; BSL2, Not applicable (non-laboratory area); BSL2; Not

applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; Not applicable (non-laboratory area); BSL2;

Containment Equipment: Not applicable; Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Not applicable; Chemical fume hood; Not applicable; Not applicable; Not applicable; Chemical fume hood; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E-1); (III-E-1); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies the genetic factors in Herpes simplex virus that contribute to its disease phenotype. Antimicrobial agents and gene therapies are tested in mouse models of disease. In this renewal, no changes to research are proposed. The IBC discussed PPE worn during activities outside of containment.

- **Bio Protocol Number: B00000124-AM009**

PI Name: Robert Landick

Protocol Title: Amendment/Renewal 009 for Biosafety Protocol for Research on Molecular Biology, Biochemistry, and Microbiology of Gene Expression and Bioenergy

Motion: IBC approved protocol

Motion Made By: Steve Garvis

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absent

Biosafety Level: BSL2; BSL1; BSL1; BSL2; BSL1; BSL1; BSL1; BSL2; BSL2;

Containment Equipment: Not applicable; Chemical fume hood; Not applicable;

Other - anaerobic chamber; Not applicable; Chemical fume hood; Chemical fume hood; Biological safety cabinet (BSC); Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-1-a) (III-D-1-b); (III-E); (III-E); (III-F-8); (III-F-1); (III-F-8); (III-F-4) (III-F-5);

Summary of IBC Review: The laboratory studies mechanisms of gene expression with a focus on RNA polymerase. The laboratory also works on engineering microbes for the production of plant-based biofuels. In this renewal, no changes to research are proposed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000173-AM017**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 017 for Genetics of infectious diseases

Motion: IBC approved protocol

Motion Made By: Warren Rose

Motion Seconded By: Peter Halfmann

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absnet

Biosafety Level: BSL1; BSL2; BSL3; BSL1; BSL2; BSL2; BSL1;

Containment Equipment: Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-E); (III-E); (III-F-8);

Summary of IBC Review: The laboratory studies the evolution of Mycobacteria. In this amendment, work with mycobacteriophages and a new strain of *M. smegmatis* is proposed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000205-AM018**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 018 for Analysis of Immunology, Virology, Genetics (by Trizol inactivation), and Pathogenesis of SIV- and Mtb-infected Macaques

Motion: IBC approved with contingencies

Motion Made By: Donna Neumann

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Matt Reynolds, abstain Greg Gauthier, absent
Biosafety Level: BSL3; BSL3; BSL2; BSL1; BSL3; BSL3; ABSL2; BSL2; BSL2; BSL2;
BSL3; ABSL2; ABSL2; BSL2; BSL2; BSL2; BSL2 - All are considered BSL2; ABSL2;
ABSL2; BSL2; BSL1, BSL2; ABSL2; BSL2; BSL2; ABSL2; BSL3; BSL3;

Containment Equipment: Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-2-a); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies simian immunodeficiency virus (SIV) in monkeys. In this amendment, a change in PPE is proposed for activities with plasma from SIV-infected animals. The IBC discussed enhanced practices for work with samples from infected animals.

- **Bio Protocol Number: B00000424-AM008**

PI Name: John Yin

Protocol Title: Amendment/Renewal 008 for Host Response to Viral Infection

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Barak Blum

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Peter Halfmann, abstain Greg Gauthier, absent

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL1; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-D-7); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E-1); (III-E-1); (III-F-8);

Summary of IBC Review: The laboratory studies viral growth in human RG2 viruses using a combination of computational modeling and wet-lab experiments. In this renewal, human rhinovirus is moved to storage only. Biosafety was adequately addressed. Minor revision is requested for congruency.

- **Bio Protocol Number: B00000475-AM019**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 019 for Comparative genomics and molecular characterization of parasitic and free-living flatworms

Motion: IBC approved with contingencies

Motion Made By: Steve Garvis

Motion Seconded By: Yevgenya Grinblat

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; ABSL2; BSL2; ABSL2; ABSL1; BSL1; BSL2; BSL1; ABSL2; BSL1; BSL2; BSL1; BSL1; BSL2; BSL2; BSL2; BSL2; BSL1; ABSL1, BSL1; ABSL2; BSL2; ABSL1, BSL1; BSL1; BSL2; BSL1; BSL1; BSL1;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood, Other - Biobubble, BSC Certification Program will do a performance test for the bioBubble.; Not applicable; Chemical fume hood; Not applicable; Chemical fume hood; Not applicable; Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research deviate from standards set by the IBC. Revisions are required for approval.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4) (III-D-4-a) (III-D-4-b); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-E-2-b-4)(III-E-2-b-5); (III-E); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies planarians, parasitic and free-living flatworms. In this renewal, updates were made to aerosol generating activities.

Revisions are needed to update new animal-specific sections added to Bio-ARROW since the last renewal.

- **Bio Protocol Number: B00000492-AM028**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 028 for Molecular Pathogenesis of Emerging Infections.

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Peter Halfmann, abstain

Biosafety Level: BSL2; ABSL2; BSL2; BSL2; ABSL2; BSL2; ABSL2; BSL2; BSL2; BSL1; ABSL2; BSL2; BSL1; BSL2; BSL2; ABSL2; ABSL2; ABSL1; BSL2; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood, Other - BioBubble; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable, Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Other - fixed samples for flow cytometry, no containment.; Biological safety cabinet (BSC); Not applicable - Fixed samples.; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Other - BSC will be housed in CIF room 1374A; Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood; Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work requires NIH approval under the NIH Guidelines. A Minor Action will be submitted. Final approval will be withheld until NIH approval is granted.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-7); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E); (III-F-8);

Summary of IBC Review: The laboratory studies emerging pathogens of humans and animals for vaccine development using a variety of animal models. This biosafety protocol covers the laboratory's work at BSL1 and BSL2. In this renewal, Elizabethkingia and activities at BSL3 have been removed (BSL3 work is now covered under biosafety protocol B00001211). The IBC supports work with highly attenuated strains of M. tuberculosis at BSL2; a Minor Action request will be submitted for NIH-OSP approval of the downgrade.

- **Bio Protocol Number: B00000514-AM008**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 008 for Regulation of Iron Homeostasis

Motion: IBC approved with contingencies

Motion Made By: Andrea Ladd

Motion Seconded By: Peter Halfmann

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absent.

Biosafety Level: BSL2 - As noted above - while there is a laminar flow hood in this room for adenoviral work that others do - we do NOT use the hood or that procedure; BSL1; BSL1; BSL1; BSL1; BSL2; BSL1; BSL1; BSL1; BSL1; BSL1, BSL2; BSL1; BSL1; BSL1;

Containment Equipment: Biological safety cabinet (BSC), Other - exhaust canopy; Chemical fume hood; Not applicable; Other - Done on the benchtop; Chemical fume hood; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Chemical fume hood; Not

applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-E); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This laboratory studies how iron metabolism is regulated in mammals and how the body controls the number of red blood cells. They use transgenic mice and cell culture models. In this renewal, no changes to research are proposed. Revisions are requested to clarify that Zymosan is in storage.

- **Bio Protocol Number: B00000537-AM004**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 004 for Lynn Group Biosafety Protocol for Cell Culture and the Biological Testing of Synthetic Materials

Motion: IBC approved with contingencies

Motion Made By: Amita Kapoor

Motion Seconded By: Barak Blum

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; Not applicable (non-laboratory area); ABSL1; Other - No BSL designated; BSL2; BSL2; ABSL1; BSL2; ABSL1; BSL2 - BSL2 signage will be used on room 1032a when non-fixed cells or tissue is present and the room is

treated as BSL2.; Other - Laboratory specialized for the handling of chemicals only;
Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Not applicable; Chemical fume hood - not used with equipment; Ventilated HEPA-filtered housing or rack system - Baker BioProtect (BSC of the Sorter), Aerosol management System (whisper Buffalo); Other - Sterilgard III Advance, Fume Hood Pioneer; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-E-1); (III-E-1); (III-F-1);

Summary of IBC Review: The laboratory studies the design of materials used to deliver therapeutic agents such as nucleic acids, peptides, and small molecules to cells in culture and animals. In this renewal, no changes to research are proposed.

Emergency response procedures need to be updated.

- **Bio Protocol Number: B00000573-AM004**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 004 for Tomotherapy and Hematopoietic Stem Cells For Tolerance To Kidney Transplants

Motion: IBC approved with contingencies

Motion Made By: Yevgenya Grinblat

Motion Seconded By: Amita Kapoor

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; ABSL2; ABSL2; ABSL2; ABSL2; BSL2; BSL2; ABSL2; ABSL2; BSL2; ABSL2; ABSL2; BSL1; ABSL2; ABSL2 - when animals present; ABSL2 - when animals present; BSL2; ABSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; ABSL2; ABSL2; ABSL2;

Containment Equipment: Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities deviate from the standards set by the IBC. Revisions are required for approval.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines:

Summary of IBC Review: The laboratory studies allogenic and xenogenic organ transplantation in nonhuman primates. In this renewal, no changes to research are proposed. Clarification is needed for activities performed at one of the locations.

- **Bio Protocol Number: B00000665-AM005**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 005 for Assessment of Selenium Status Using

Molecular Biology Markers

Motion: IBC approved protocol

Motion Made By: Andrea Ladd

Motion Seconded By: Peter Halfmann

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absent.

Biosafety Level: ABSL1, BSL1; BSL1; BSL1; ABSL1, BSL1; BSL1; ABSL1, BSL1; ABSL1, BSL1;

Containment Equipment: Not applicable, Other - Animal changing station; Not applicable, Other - Autoclave; Not applicable; Not applicable; Not applicable; Chemical fume hood; Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-E); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies the biological roles of selenium and how it is regulated. They use genetically modified rodent models as well as wild type turkeys and chickens. In this renewal, cell culture studies were removed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000799-AM006**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 006 for Gut microbial diversity and function in insect disease vectors

Motion: IBC approved protocol

Motion Made By: Gregory Gauthier

Motion Seconded By: Joel Malak

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL2, BSL2; BSL1; Not applicable (non-laboratory area); ABSL2, BSL2; ABSL1; ABSL2, BSL2; BSL2; BSL2; ABSL2, BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a)(III-D-1-b); (III-E); (III-F-8); (III-F-1); (III-F-4) (III-F-5);

Summary of IBC Review: The laboratory studies the microbiome of insect disease vectors using flies and mosquitos as models. In this amendment, addition of an antibiotic-resistant strain of RG2 bacteria is proposed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00001010-AM003**

PI Name: Bruce Barrett

Protocol Title: Amendment/Renewal 003 for Barrett/Temte Biosafety Protocol for Respiratory Infection Studies

Motion: IBC approved with contingencies

Motion Made By: Joel Malak

Motion Seconded By: Peter Halfmann

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: Other - Clinical Space; Other - Clinical Space; Other - Clinical Space;

Containment Equipment: Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines:

Summary of IBC Review: The laboratory studies respiratory illnesses. Research studies are conducted in a clinical setting. In this amendment, experiments testing the efficacy and usability of a rapid test for SARS-CoV-2 and Influenza viruses are proposed. The IBC had no biosafety concerns. Minor revisions are needed for clarification.

- **Bio Protocol Number: B00001080-AM004**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 004 for Gene Regulatory Mechanisms Mediating Homeostasis and Neurodegenerative Disease

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Donna Neumann

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL1; BSL1; ABSL2; BSL1; BSL1; BSL2; ABSL2; ABSL2; BSL1;

Containment Equipment: Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC);

Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system;

Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system;

Other - Downdraft Tables;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E-1); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies the neurodegenerative disease Amyotrophic Lateral Sclerosis using a mouse model. In this amendment, work with a replication incompetent canine adenovirus type 2 (CAV2) viral vector is proposed. More details are requested regarding genes expressed by the CAV2.

- **Bio Protocol Number: B00001160-AM002**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 002 for Human metapneumovirus (HMPV) immunity and pathogenesis

Motion: IBC approved protocol

Motion Made By: Donna Neumann

Motion Seconded By: Joel Malak

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; ABSL2; BSL2 - BSL2;

Containment Equipment: Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies mechanisms of immunity and pathogenesis for human metapneumovirus in cell and animal models. The laboratory also studies molecular viral diagnostics. In this amendment, work with non-recombinant respiratory syncytial virus is proposed. Biosafety is adequately addressed.

The IBC voted unanimously to adopt revisions to IBC Policy UW-6102. The revisions change the required frequency of renewal to adopt a tiered schedule based on level of risk, with higher risk requiring more frequent renewal and lower risk requiring less frequent renewal. Andrea Ladd made the motion. Garret Suen seconded the motion. Greg Gauthier was absent.

University of Wisconsin-Madison Institutional Biosafety Committee

Minutes of Regular Meeting Closed Session

Date: 8/6/2025

Present: Peter Halfmann, Matt Reynolds, Donna Neumann, Yevgenya Grinblat, Andrea Ladd, Warren Rose, Amita Kapoor, Gregory Gauthier, Ryan Stoffel, Garret Suen, Joel Malak, Clint Morgan, Barak Blum, Steve Garvis

Consultants: Tony Mcgrath, Lissa Koop, Darren Berger, Christina Pier, Carrie Ensrud, John Cejka, Quin Koehl

OBS: Tony Mcgrath, David Dyer, Karen Demick, Christina Pier, Andrea Ladd, Louise Meske, Stephanie Kutz, Tara Schnell, Megan Dixon, Erin Plisch, Donald Busalacchi, Carrie Ensrud, Kathy Krasny, Quin Koehl

Guests: Sarah Johnson-Schlueter, CALS

Call to order: The meeting was called to order by Garret Suen, at Zoom at 1:32 PM

Announcements: The IBC meeting is closed to the public.

Review of Minutes: A motion to approve the closed session minutes of the following IBC meetings was Unanimously adopted.

Institutional Biosafety Committee meeting on (7/23/2025)

Greg Gauthier, absent

Other business - closed session

- **Agenda Items - Documents For Closed Session:**

Review of research protocols - closed session

Review of research amendments - closed session

🔍 B00000835-AM010

Announcements

null

The meeting adjourned 2:39 PM

- **Bio Protocol Number: B00000835-AM010**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 010 for Pathogenesis of Staphylococcus aureus and Neisseria gonorrhoeae

Motion: IBC approved with contingencies

Motion Made By: Warren Rose

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees: Greg Gauthier, absent

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; BSL2; ABSL2; ABSL2; ABSL2; ABSL2; BSL2;

Containment Equipment: Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Other - centrifuges, microscopes; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Not applicable; Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities deviate from the standards set by the IBC. Revisions are required for approval.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a)(III-D-1-b); (III-E); (III-E-1); (III-F-8); (III-F-8);

Summary of IBC Review: The laboratory studies virulence mechanisms in *Staphylococcus aureus* and *Neisseria gonorrhea*. In this renewal, work with a pathogenic *E. coli* and superantigens of the enterotoxin gene cluster and new locations are proposed. Biosafety was adequately addressed for new work. Addition of new locations require additional documentation prior to approval.

Andrea Ladd gave the IBC incident report.